All PlansCoverageLow impact
Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology·Medical Policy
We identified it
Jun 20, 2026
Summary
This is an established policy (not a new change) regarding radioimmunotherapy for Non-Hodgkin Lymphoma treatment. The policy defines coverage criteria for ibritumomab tiuxetan (Zevalin) as medically necessary for specific conditions including relapsed/refractory lymphoma and consolidation therapy, while considering certain uses investigational.
Action Required
Review existing billing practices for radioimmunotherapy treatments to ensure compliance with current coverage criteria. Verify that ibritumomab tiuxetan (Zevalin) claims meet the medically necessary conditions outlined in the policy before submission.